478 related articles for article (PubMed ID: 12857560)
21. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
22. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
23. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
Thiede Ch; Lutterbeck K; Oelschlägel U; Kiehl M; Steudel Ch; Platzbecker U; Brendel C; Fauser AA; Neubauer A; Ehninger G; Bornhäuser M
Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
[TBL] [Abstract][Full Text] [Related]
24. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
25. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
[TBL] [Abstract][Full Text] [Related]
26. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
[TBL] [Abstract][Full Text] [Related]
27. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
[TBL] [Abstract][Full Text] [Related]
28. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Hassan M
Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
[TBL] [Abstract][Full Text] [Related]
29. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
[TBL] [Abstract][Full Text] [Related]
30. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms.
Jiménez-Velasco A; Barrios M; Román-Gómez J; Navarro G; Buño I; Castillejo JA; Rodríguez AI; García-Gemar G; Torres A; Heiniger AI
Leukemia; 2005 Mar; 19(3):336-43. PubMed ID: 15674363
[TBL] [Abstract][Full Text] [Related]
31. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
32. Repetitive DNA polymorphisms in following chimerism after allogeneic bone marrow transplantation.
Grubic Z; Stingl K; Cecuk Jelicic E; Zunec R; Kastelan A; Serventi Seiwerth R; Bogdanic V; Labar B; Kerhin Brkljacic V
Clin Transplant; 2005 Oct; 19(5):586-90. PubMed ID: 16146548
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of mixed hematopoietic chimerism in pediatric patients with leukemia after allogeneic stem cell transplantation by quantitative PCR analysis of variable number of tandem repeat and testis determination gene.
Wang LJ; Chou P; Gonzalez-Ryan L; Huang W; Haut PR; Kletzel M
Bone Marrow Transplant; 2002 Jan; 29(1):51-6. PubMed ID: 11840144
[TBL] [Abstract][Full Text] [Related]
34. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
35. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival.
Lamba R; Abella E; Kukuruga D; Klein J; Savasan S; Abidi MH; Mohamed A; Peres E
Leukemia; 2004 Oct; 18(10):1681-6. PubMed ID: 15318247
[TBL] [Abstract][Full Text] [Related]
36. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
39. Predicting outcomes of HLA-identical allogeneic stem cell transplants from variable number of tandem repeat disparity between donors and recipients.
Kim DH; Jung HD; Kwack DH; Lee NY; Sohn SK; Baek JH; Kim JG; Suh JS; Lee KB; Shin IH
Haematologica; 2006 Jan; 91(1):71-7. PubMed ID: 16434373
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome.
Bacigalupo A; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; Ibatici A; di Grazia C; Dominietto A; Piaggio G; Podesta M; Bruno B; Lombardi A; Frassoni F; Viscoli C; Sacchi N; Van Lint MT
Bone Marrow Transplant; 2007 Mar; 39(6):341-6. PubMed ID: 17277788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
